March 7, 2019 — Rising incidence of congenital heart disease and increasing awareness of transcatheter pulmonary valve (TPV) therapy is expected to drive growth in the TPV market, according to Reports and Data, reaching a value of $66.4 million by 2026.
Transcatheter pulmonary valve therapy has come up as the treatment of choice in most congenital heart disease patients with degeneration of a previous right ventricular outflow tract repair. To avoid the need for repeat median sternotomy procedures, less invasive catheter-based interventions to treat pulmonary valve dysfunction have been developed over time.
In the United States, the incidence of congenital heart defects ranges between four to 10 cases per 1,000, clustering around 8 cases per 1,000 live births. Continental variations in birth prevalence have been observed, from about 6.9 cases per 1,000 births in Europe to 9.3 cases per 1,000 births in Asia. However, the relationship between valve size and balloon waist may reflect selection and procedural bias, which is likely to hinder the market growth
Further key findings from the report suggest
- The TPV therapy market is rising at a high growth rate of 7.2 percent in Asia Pacific followed by North America and Europe. High incidence of cardiovascular diseases will drive the demand for the market during forecast period across all regions;
- The valuation for balloon-expanded transcatheter valve market was $30.5 million in 2017 and is expected to grow to $53 million by 2026.
- Asia Pacific is expected to witness a CAGR of 12.9 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth; and
- Regional reimbursement scenarios are another key regulatory factor for adoption and growth of transcatheter pulmonary valve therapy in the region.
Key participants discussed in the report include Medtronic, Edward Lifesciences, Cryolife Inc. and Venus Medtech.
For more information: www.reportsanddata.com